SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Charlie Smith who wrote (700)9/26/1998 3:49:00 PM
From: MGV  Read Replies (1) of 1754
 
Hey Charlie.

What I have to add about the VISX claim against Autonomous you may already know but, here it is:

I understand the claim is a counterclaim to an action brought by Autonomous seeking a declaratory judgement that VISX's L'Esperance patent is invalid. Apparently, VLNC and Autonomous had been negotiating settlement/licensing terms after the declaratory J action was filed. The settlement negotiations presumably broke down. Consequently, the VISX counterclaim followed.

What I don't know is how central the L'Esperance patents are to the VISX laser. It is the Trokiel patents that are at issue with the FTC, if I recall correctly. If Autonomous were to have the L'esperance patents invalidated and the FTC overturns the Trokiel patents, what licensing leverage does VISX retain?

Intellectual property issues must be impacting the stock price. I wonder to what extent it is?

- Mark
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News